NYSE:EW Edwards Lifesciences (EW) Stock Forecast, Price & News $79.41 +1.13 (+1.44%) (As of 08/11/2023 08:48 PM ET) Add Compare Share Share Today's Range$77.90▼$79.5850-Day Range$77.97▼$94.3352-Week Range$67.13▼$105.45Volume3.90 million shsAverage Volume3.15 million shsMarket Capitalization$48.27 billionP/E Ratio35.14Dividend YieldN/APrice Target$92.68 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Edwards Lifesciences MarketRank™ ForecastAnalyst RatingHold2.39 Rating ScoreUpside/Downside16.7% Upside$92.68 Price TargetShort InterestHealthy1.58% of Float Sold ShortDividend StrengthN/ASustainability-0.95Upright™ Environmental ScoreNews Sentiment-0.21Based on 18 Articles This WeekInsider TradingSelling Shares$12.76 M Sold Last QuarterProj. Earnings Growth12.94%From $2.55 to $2.88 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.66 out of 5 starsMedical Sector92nd out of 987 stocksSurgical Appliances & Supplies Industry4th out of 20 stocks 3.2 Analyst's Opinion Consensus RatingEdwards Lifesciences has received a consensus rating of Hold. The company's average rating score is 2.39, and is based on 8 buy ratings, 9 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $92.68, Edwards Lifesciences has a forecasted upside of 16.7% from its current price of $79.41.Amount of Analyst CoverageEdwards Lifesciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.58% of the float of Edwards Lifesciences has been sold short.Short Interest Ratio / Days to CoverEdwards Lifesciences has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Edwards Lifesciences has recently decreased by 2.87%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEdwards Lifesciences does not currently pay a dividend.Dividend GrowthEdwards Lifesciences does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEdwards Lifesciences has received a 54.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Catheters", "Mitral valve repair devices", and "Artificial heart valves" products. See details.Environmental SustainabilityThe Environmental Impact score for Edwards Lifesciences is -0.95. Previous Next 1.5 News and Social Media Coverage News SentimentEdwards Lifesciences has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Edwards Lifesciences this week, compared to 7 articles on an average week.Search Interest19 people have searched for EW on MarketBeat in the last 30 days. This is an increase of 12% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Edwards Lifesciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Edwards Lifesciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,763,159.00 in company stock.Percentage Held by InsidersOnly 1.29% of the stock of Edwards Lifesciences is held by insiders.Percentage Held by Institutions79.78% of the stock of Edwards Lifesciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Edwards Lifesciences are expected to grow by 12.94% in the coming year, from $2.55 to $2.88 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Edwards Lifesciences is 35.14, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.71.Price to Earnings Ratio vs. SectorThe P/E ratio of Edwards Lifesciences is 35.14, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 132.22.Price to Earnings Growth RatioEdwards Lifesciences has a PEG Ratio of 4.29. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioEdwards Lifesciences has a P/B Ratio of 7.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Edwards Lifesciences (NYSE:EW) StockEdwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.Read More EW Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EW Stock News HeadlinesAugust 11, 2023 | americanbankingnews.comCatherine M. Szyman Sells 5,000 Shares of Edwards Lifesciences Co. (NYSE:EW) StockAugust 10, 2023 | realmoney.thestreet.comEdwards Lifesciences Suffers a Downgrade by Our Quantitative ServiceAugust 14, 2023 | Chaikin Analytics (Ad)Man Behind Wall Street AI Issues Urgent BUYIt flashed bullish on all 10 of the top 10 stocks of 2022 – detecting rare 100% winners during the worst year for stocks since 2008. Here’s its top pick for 2023 (name and ticker).August 10, 2023 | finance.yahoo.comEdwards Lifesciences: When Two Out of Three IS BadAugust 9, 2023 | americanbankingnews.comZacks Research Equities Analysts Cut Earnings Estimates for Edwards Lifesciences Co. (NYSE:EW)August 9, 2023 | americanbankingnews.comMichael A. Mussallem Sells 29,350 Shares of Edwards Lifesciences Co. (NYSE:EW) StockAugust 8, 2023 | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) Given Average Recommendation of "Hold" by AnalystsAugust 6, 2023 | americanbankingnews.comEdwards Lifesciences Co. (NYSE:EW) Receives $92.68 Average PT from BrokeragesAugust 14, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...August 4, 2023 | finance.yahoo.comBruker (BRKR) Q2 Earnings and Revenues Top, '23 Sales View UpAugust 3, 2023 | markets.businessinsider.comCredit Suisse Reaffirms Their Hold Rating on Edwards Lifesciences (EW)August 1, 2023 | finance.yahoo.comWhy Edwards Lifesciences Corporation (NYSE:EW) Could Be Worth WatchingJuly 29, 2023 | investing.comEdwards Lifesciences shares decline as growth disappoints investorsJuly 29, 2023 | msn.comJP Morgan Maintains Edwards Lifesciences (EW) Overweight RecommendationJuly 28, 2023 | finance.yahoo.comAcadia Healthcare (ACHC) Q2 Earnings Beat on Higher AdmissionsJuly 28, 2023 | finance.yahoo.comIn the wake of Edwards Lifesciences Corporation's (NYSE:EW) latest US$6.1b market cap drop, institutional owners may be forced to take severe actionsJuly 27, 2023 | finanznachrichten.deEdwards Lifesciences Corporation: Edwards Lifesciences Reports Second Quarter ResultsJuly 27, 2023 | markets.businessinsider.comBarclays Remains a Buy on Edwards Lifesciences (EW)July 27, 2023 | finance.yahoo.comQ2 2023 Edwards Lifesciences Corp Earnings CallJuly 27, 2023 | markets.businessinsider.comEdwards Lifesciences Corp. Q2 Profit Decreases, but beats estimatesJuly 27, 2023 | reuters.comEdwards Lifesciences shares fall as slow heart-valve growth dulls forecast raiseJuly 27, 2023 | msn.comJefferies Maintains Edwards Lifesciences (EW) Buy RecommendationJuly 27, 2023 | markets.businessinsider.comBank of America Securities Remains a Hold on Edwards Lifesciences (EW)July 27, 2023 | finance.yahoo.comEdwards Lifesciences Sinks Despite An Earnings Beat, Outlook IncreaseJuly 27, 2023 | finance.yahoo.comEdwards Lifesciences (EW) Surpasses Q2 Earnings and Revenue EstimatesJuly 27, 2023 | finance.yahoo.comCompared to Estimates, Edwards Lifesciences (EW) Q2 Earnings: A Look at Key MetricsJuly 25, 2023 | finance.yahoo.comMedTech Stocks' Q2 Earnings Due on Jul 26: DGX, TMO and MoreSee More Headlines Receive EW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edwards Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EW Company Calendar Last Earnings7/26/2023Today8/14/2023Next Earnings (Estimated)10/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Surgical appliances & supplies Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNYSE:EW CUSIP28176E10 CIK1099800 Webwww.edwards.com Phone(949) 250-2500Fax949-250-2525Employees17,300Year Founded1958Price Target and Rating Average Stock Price Forecast$92.68 High Stock Price Forecast$110.00 Low Stock Price Forecast$66.00 Forecasted Upside/Downside+16.7%Consensus RatingHold Rating Score (0-4)2.39 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$2.26 Trailing P/E Ratio35.14 Forward P/E Ratio31.14 P/E Growth4.29Net Income$1.52 billion Net Margins24.56% Pretax Margin28.35% Return on Equity25.43% Return on Assets18.04% Debt Debt-to-Equity Ratio0.09 Current Ratio3.15 Quick Ratio2.30 Sales & Book Value Annual Sales$5.38 billion Price / Sales8.97 Cash Flow$2.73 per share Price / Cash Flow29.05 Book Value$10.60 per share Price / Book7.49Miscellaneous Outstanding Shares607,920,000Free Float600,074,000Market Cap$48.27 billion OptionableOptionable Beta1.02 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Bernard J. Zovighian (Age 55)CEO & Director Comp: $1.04MMr. Scott B. Ullem (Age 56)Corp. VP & CFO Comp: $1.09MMr. Larry L. Wood (Age 57)Corp. VP and Group Pres of TAVR & Surgical Structural Heart Comp: $1.1MMr. Jean-Luc Lemercier (Age 66)Corp. VP of Japan, Asia Pacific & Greater China Comp: $1.24MDr. Todd J. Brinton FACCM.D., Corp. VP of Advanced Technology & Chief Scientific OfficerMark WilterdingVP of Investor RelationsMr. Arnold A. Pinkston (Age 64)Corp. VP & Gen. Counsel Mr. Dirksen J. LehmanCorp. VP of Public AffairsMr. Donald E. Bobo Jr. (Age 61)Corp. VP of Strategy & Corp. Devel. Ms. Christine Z. McCauley (Age 58)Corp. VP of HR More ExecutivesKey CompetitorsSTERISNYSE:STEIntuitive SurgicalNASDAQ:ISRGAlign TechnologyNASDAQ:ALGNZimmer BiometNYSE:ZBHSmith & NephewNYSE:SNNView All CompetitorsInsiders & InstitutionsCapital International Ltd. CABought 162 shares on 8/11/2023Ownership: 0.021%D.A. Davidson & CO.Bought 344 shares on 8/11/2023Ownership: 0.007%Natixis Investment Managers InternationalBought 336 shares on 8/11/2023Ownership: 0.002%E Fund Management Co. Ltd.Sold 323 shares on 8/11/2023Ownership: 0.000%Covestor LtdSold 352 shares on 8/11/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EW Stock - Frequently Asked Questions Should I buy or sell Edwards Lifesciences stock right now? 18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 1 sell rating, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EW shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EW, but not buy additional shares or sell existing shares. View EW analyst ratings or view top-rated stocks. What is Edwards Lifesciences' stock price forecast for 2023? 18 equities research analysts have issued 1-year price targets for Edwards Lifesciences' shares. Their EW share price forecasts range from $66.00 to $110.00. On average, they predict the company's share price to reach $92.68 in the next year. This suggests a possible upside of 16.7% from the stock's current price. View analysts price targets for EW or view top-rated stocks among Wall Street analysts. How have EW shares performed in 2023? Edwards Lifesciences' stock was trading at $74.61 at the beginning of 2023. Since then, EW shares have increased by 6.4% and is now trading at $79.41. View the best growth stocks for 2023 here. When is Edwards Lifesciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. View our EW earnings forecast. How were Edwards Lifesciences' earnings last quarter? Edwards Lifesciences Co. (NYSE:EW) issued its quarterly earnings results on Wednesday, July, 26th. The medical research company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.01. The medical research company earned $1.53 billion during the quarter, compared to analyst estimates of $1.51 billion. Edwards Lifesciences had a trailing twelve-month return on equity of 25.43% and a net margin of 24.56%. Edwards Lifesciences's quarterly revenue was up 11.4% on a year-over-year basis. During the same period last year, the business posted $0.63 EPS. Read the conference call transcript. What ETFs hold Edwards Lifesciences' stock? ETFs with the largest weight of Edwards Lifesciences (NYSE:EW) stock in their portfolio include iShares U.S. Medical Devices ETF (IHI), Neuberger Berman Disrupters ETF (NBDS), Global X Aging Population ETF (AGNG), First Trust Indxx Medical Devices ETF (MDEV), ETC 6 Meridian Quality Growth ETF (SXQG), BNY Mellon Sustainable US Equity ETF (BKUS), Goldman Sachs Future Health Care Equity ETF (GDOC) and Inspire 100 ETF (BIBL). When did Edwards Lifesciences' stock split? Shares of Edwards Lifesciences split on Friday, May 29th 2020. The 3-1 split was announced on Thursday, May 7th 2020. The newly created shares were issued to shareholders after the market closes on Monday, May 18th 2020. An investor that had 100 shares of stock prior to the split would have 300 shares after the split. What guidance has Edwards Lifesciences issued on next quarter's earnings? Edwards Lifesciences updated its third quarter 2023 earnings guidance on Wednesday, July, 26th. The company provided earnings per share guidance of $0.55-$0.61 for the period, compared to the consensus estimate of $0.63. The company issued revenue guidance of $1.44 billion-$1.52 billion, compared to the consensus revenue estimate of $1.47 billion. What is Michael A. Mussallem's approval rating as Edwards Lifesciences' CEO? 389 employees have rated Edwards Lifesciences Chief Executive Officer Michael A. Mussallem on Glassdoor.com. Michael A. Mussallem has an approval rating of 90% among the company's employees. What other stocks do shareholders of Edwards Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edwards Lifesciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Salesforce (CRM), Walt Disney (DIS), Visa (V), Johnson & Johnson (JNJ), QUALCOMM (QCOM), Micron Technology (MU) and CVS Health (CVS). What is Edwards Lifesciences' stock symbol? Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW." Who are Edwards Lifesciences' major shareholders? Edwards Lifesciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (125.25%), BlackRock Inc. (8.36%), Capital International Investors (4.44%), Bank of New York Mellon Corp (2.91%), Brown Advisory Inc. (2.36%) and Geode Capital Management LLC (2.04%). Insiders that own company stock include Bernard J Zovighian, Catherine M Szyman, Catherine M Szyman, Daveen Chopra, Donald E Bobo Jr, Heisz Leslie Stone, Huimin Wang, Jean-Luc M Lemercier, Kieran Gallahue, Larry L Wood, Martha H Marsh, Michael A Mussallem, Michael A Mussallem, Nicholas J Valeriani, Robert WA Sellers and Scott B Ullem. View institutional ownership trends. How do I buy shares of Edwards Lifesciences? Shares of EW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Edwards Lifesciences' stock price today? One share of EW stock can currently be purchased for approximately $79.41. How much money does Edwards Lifesciences make? Edwards Lifesciences (NYSE:EW) has a market capitalization of $48.27 billion and generates $5.38 billion in revenue each year. The medical research company earns $1.52 billion in net income (profit) each year or $2.26 on an earnings per share basis. How many employees does Edwards Lifesciences have? The company employs 17,300 workers across the globe. Does Edwards Lifesciences have any subsidiaries? The following companies are subsidiares of Edwards Lifesciences: BMEYE, CAS Medical Systems, CardiAQ Valve Technologies, Edwards Lifesciences (Japan) Limited, Edwards Lifesciences AG, Edwards Lifesciences Holding B.V., Edwards Lifesciences Innovation Holding LLC, Edwards Lifesciences LLC, Edwards Lifesciences Services GmbH, Embrella Cardiovascular, Harpoon Medical, Myocor, Percutaneous Valve Technologies, Valtech Cardio, and Whitland Research.Read More How can I contact Edwards Lifesciences? Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The official website for the company is www.edwards.com. The medical research company can be reached via phone at (949) 250-2500, via email at investor_relations@edwards.com, or via fax at 949-250-2525. This page (NYSE:EW) was last updated on 8/14/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edwards Lifesciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.